1. At a Glance
Suraksha Diagnostic Ltd walks into FY26 like a freshly listed student from a strict convent school — disciplined margins, decent marks, but everyone is still judging the uniform. With a market cap of ~₹1,498 Cr, CMP ~₹288, and a P/E hovering around 45×, this diagnostics player is clearly priced like a premium pathology brand, even though it is geographically glued to West Bengal for 100% of revenue.
The latest Q3 FY26 performance shows ₹77.7 Cr in quarterly revenue (+30.6% YoY) and PAT of ₹7.24 Cr (+22.3% YoY). Operating margins remain chunky at ~30%, which is rare air in diagnostics. Add to that EBITDA per patient of ₹715 and average revenue per patient of ₹2,118, and you get a business that knows how to monetise every blood sample and MRI scan like a seasoned Bengali sweet shop owner pricing mishti doi during Durga Puja.
But before we clap too hard — the stock is down ~19% since listing, debt stands at ₹118 Cr, promoter stake is 49%, and the entire IPO was an Offer for Sale. No fresh cash. No balance sheet fireworks. Just promoters ringing the bell and exiting partially. Curious already?
2. Introduction
Suraksha Diagnostic is not your pan-India lab chain with glossy airports labs and metro ads. It is a deeply regional, execution-heavy, B2C-first diagnostic machine, born in 2005 and sharpened over two decades in Eastern India. Think of it as a Bengal-focused healthcare utility — blood tests, MRIs, CT scans, ultrasounds, plus doctor consultations, all bundled into one ecosystem.
The company finally came to Dalal Street in December 2024, raising ₹846 Cr via IPO, all OFS. That single line itself split investor opinion into
